Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. (Nasdaq: IMMX) generates a steady flow of news as a clinical-stage biopharmaceutical company advancing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases. The company describes itself as a global leader in this rare blood disorder, and its news coverage reflects progress in clinical development, regulatory interactions, capital formation and corporate governance.
Many Immix Biopharma news items focus on its lead BCMA-targeted CAR-T cell therapy, NXC-201, and the ongoing NEXICART-2 clinical trial in relapsed/refractory AL amyloidosis. Press releases highlight interim and Phase 2 results, including complete response rates, organ responses and safety observations, as well as the selection of NXC-201 data for oral presentations at major conferences such as ASH and ASCO. The company also reports on regulatory designations for NXC-201, including RMAT and Orphan Drug Designation from U.S. and European authorities.
Investors following IMMX news will also see announcements about equity financings, including registered underwritten offerings and private placements of common stock and warrants, together with stated uses of proceeds for NXC-201 development and general corporate purposes. Additional coverage includes board and management changes, such as the appointment of experienced biotechnology leaders to the board of directors and the addition of a Chief Commercial Officer to prepare for potential commercialization of NXC-201.
This news page aggregates company press releases and related updates so readers can track Immix Biopharma’s clinical milestones, financing activities, conference presentations and strategic appointments over time.
Immix Biopharma (NASDAQ:IMMX) will participate in the Jefferies Global Healthcare Conference June 2-4, 2026 in New York.
The company said it will host one-on-one institutional investor meetings and that a replay link will be posted to its Presentation & Events page on the investor website when available.
Immix Biopharma (NASDAQ:IMMX) announced completion of enrollment in its BLA‑enabling NEXICART‑2 trial for relapsed/refractory AL amyloidosis, meeting prior guidance. Topline NEXICART‑2 results are expected in Q3 2026, followed by a planned BLA submission and intended commercial launch.
The company also appointed Dr. Richard Graydon as Chief Medical Officer; Dr. Graydon has led new and supplemental drug and biologics applications at Merck and Johnson & Johnson for multiple approved therapies.
Immix Biopharma (NASDAQ:IMMX) will present and host investor meetings at two institutional conferences in Miami Beach in March 2026. Management will attend the Leerink Partners 2026 Global Healthcare Conference March 8–11 and Citizens Life Sciences Conference March 10–11, 2026.
One-on-one meetings are available via conference representatives; replay links will be posted on the company Presentation & Events page when available.
Immix Biopharma (NASDAQ: IMMX) announced that the U.S. FDA has granted Breakthrough Therapy Designation to NXC-201 for relapsed/refractory AL amyloidosis based on positive NEXICART-2 Phase 2 interim results presented at ASH on December 7, 2025. Final NEXICART-2 data are expected in 2026, with a planned BLA submission this year. Management said the designation recognizes NXC-201 as the only FDA breakthrough granted among therapies in active development for this indication and reiterated plans to complete enrollment and pursue regulatory filing.
Immix Biopharma (NASDAQ:IMMX) announced the closing of an upsized underwritten registered offering on Dec 9, 2025 consisting of 19,117,646 shares of common stock at $5.10 per share and 490,196 pre-funded warrants at $5.09 each.
Net proceeds to the company after underwriting discounts, commissions and offering expenses were approximately $93.7 million. The financing included leading U.S. biotechnology institutional investors and mutual funds, with Morgan Stanley as sole book‑running manager and Citizens Capital Markets and Mizuho as co‑managers.
The securities were offered under a shelf registration statement (Form S-3, File No. 333-269100) declared effective Jan 11, 2023; a prospectus supplement was filed with the SEC and is available on the SEC website.
Immix Biopharma (NASDAQ:IMMX) priced an underwritten offering of 19,117,646 common shares at $5.10 each and pre-funded warrants to purchase 490,196 shares at $5.09 per warrant, for expected gross proceeds of $100 million.
The offering is expected to close on or about December 9, 2025, subject to customary closing conditions. Immix intends to use net proceeds to fund NXC-201 development, working capital and general corporate purposes, and says cash plus expected CIRM grant disbursements should fund operations into mid-2027. Morgan Stanley is sole book-runner; Citizens Capital Markets and Mizuho are co-managers. Securities are offered under a Form S-3 shelf registration.
Immix Biopharma (NASDAQ:IMMX) reported positive Phase 2 results for NXC-201 at ASH 2025 with an independent review committee complete response (CR) rate of 75% (15/20) at s/u IFE(-).
MRD negativity in bone marrow was observed in 4 of 5 pending patients, which the company says could raise the CR to 95%. Downstream organ responses occurred in 70% of evaluable patients (7/10). No neurotoxicity and only low-grade cytokine release syndrome (median duration 1 day) were reported. NEXICART-2 final readout and planned BLA submission in 2026. Data cutoff: Nov 13, 2025.
Immix Biopharma (NASDAQ:IMMX) appointed Michael Grabow as Chief Commercial Officer effective Nov 12, 2025 to lead U.S. commercialization and launch of NXC-201 in relapsed/refractory AL amyloidosis. The company highlighted Michael’s >25 years of commercialization experience and his role leading MODEYSO® go-to-market at Chimerix, which was acquired by Jazz for $935 million in 2025. Immix noted NXC-201 has received RMAT and Orphan Drug Designation from the FDA and positions a one-and-done approach for a disease with no currently approved FDA therapies.
Immix Biopharma (NASDAQ: IMMX) announced that interim Phase 1/2 results from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL amyloidosis were selected for an oral presentation at ASH 2025.
The oral presentation is scheduled for December 7, 2025, 5:45–6:00 PM ET (Abstract abs25-14730) in Session 652: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias. The presentation covers first 20-patient safety and efficacy data from NEXICART-2, described as the first U.S. CAR-T trial in relapsed/refractory light-chain (AL) amyloidosis. Event details are available on Immix Biopharma’s investor presentations page.
Immix Biopharma (NASDAQ: IMMX) will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, November 10-12, 2025.
Management will participate in a Fireside Chat on November 11, 2025 at 12:30 PM ET and will be available for one-on-one meetings by request through Guggenheim representatives. A replay link will be posted on the company’s Investors > Presentation & Events page when available.